Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

Maximizing the Benefit of RAS Blockade in Diabetic Nephropathy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00240019

Enrollment

Registered

2005-10-17

Start date

2003-12-31

Completion date

2006-04-30

Last updated

2006-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Brief summary

The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.

Interventions

DRUGAddition of furosemide 20 mg oral bid to baseline regimen

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

proteinuria greater than 1 gram/day serum creatinine \< 2.6 for men, \< 2.0 for women

Exclusion criteria

blood pressure which cannot be controlled without a diuretic renal diseases other than diabetic nephropathy other disease which would alter renal function during 6 months

Design outcomes

Primary

Measure	Time frame
The amount of protein in the urine after 8 weeks of treatment.	—

Secondary

Measure	Time frame
The estimated glomerular filtration rate after 8 weeks of treatment.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026